Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK.

Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.

PMID:
29848569
2.

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, Kaufmann E, Ravichandran V, Mukherjee S, Berger MF, Hyman DM, Klimstra DS, Abou-Alfa GK, Tjan C, Covington C, Maynard H, Allen PJ, Askan G, Leach SD, Iacobuzio-Donahue CA, Robson ME, Offit K, Stadler ZK, O'Reilly EM.

J Natl Cancer Inst. 2018 Feb 28. doi: 10.1093/jnci/djy024. [Epub ahead of print]

PMID:
29506128
3.

Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?

Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM.

Clin Colorectal Cancer. 2018 Jun;17(2):e315-e321. doi: 10.1016/j.clcc.2018.01.009. Epub 2018 Feb 7.

PMID:
29496399
4.

Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma.

Mier-Hicks A, Raj M, Do RK, Yu KH, Lowery MA, Varghese A, O'Reilly EM.

Clin Colorectal Cancer. 2018 Jun;17(2):121-128. doi: 10.1016/j.clcc.2018.01.008. Epub 2018 Jan 31.

PMID:
29477452
5.

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM.

Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.

PMID:
29367431
6.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.

Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.

PMID:
29338080
7.

Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review.

Hicks AM, DeRosa A, Raj M, Do R, Yu KH, Lowery MA, Varghese A, O'Reilly EM.

Clin Colorectal Cancer. 2018 Jun;17(2):e207-e216. doi: 10.1016/j.clcc.2017.12.001. Epub 2017 Dec 12. Review.

PMID:
29306522
8.

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.

Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

PMID:
29295881
9.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.

Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.

PMID:
29223478
10.

Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients.

Chakraborty J, Langdon-Embry L, Cunanan KM, Escalon JG, Allen PJ, Lowery MA, O'Reilly EM, Gönen M, Do RG, Simpson AL.

PLoS One. 2017 Dec 7;12(12):e0188022. doi: 10.1371/journal.pone.0188022. eCollection 2017.

11.

Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy.

Jordan EJ, Basturk O, Shia J, Klimstra DS, Alago W, D'Angelica MI, Abou-Alfa GK, O'Reilly EM, Lowery MA.

J Gastrointest Oncol. 2017 Oct;8(5):E65-E72. doi: 10.21037/jgo.2017.06.21.

12.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.

JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137.

13.

A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.

Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, Covington CM, Brenner R, Hollywood E, Barba A, Johnston A, Liu KC, Feng X, Capanu M, Abou-Alfa GK, O'Reilly EM.

Cancer. 2017 Dec 1;123(23):4556-4565. doi: 10.1002/cncr.30897. Epub 2017 Aug 18.

PMID:
28832976
14.

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model.

Hajj C, Russell J, Hart CP, Goodman KA, Lowery MA, Haimovitz-Friedman A, Deasy JO, Humm JL.

Transl Oncol. 2017 Oct;10(5):760-765. doi: 10.1016/j.tranon.2017.06.010. Epub 2017 Jul 31.

15.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004c. No abstract available.

PMID:
28777785
16.

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.

Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, Leach T, Herbst B, Askan G, Maynard H, Glassman D, Covington C, Schultz N, Abou-Alfa GK, Harding JJ, Klimstra DS, Hechtman JF, Hyman DM, Allen PJ, Jarnagin WR, Balachandran VP, Varghese AM, Schattner MA, Yu KH, Saltz LB, Solit DB, Iacobuzio-Donahue CA, Leach SD, O'Reilly EM.

Clin Cancer Res. 2017 Oct 15;23(20):6094-6100. doi: 10.1158/1078-0432.CCR-17-0899. Epub 2017 Jul 28.

PMID:
28754816
17.

Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.

Park JJ, Hajj C, Reyngold M, Shi W, Zhang Z, Cuaron JJ, Crane CH, O'Reilly EM, Lowery MA, Yu KH, Goodman KA, Wu AJ.

Acta Oncol. 2017 Dec;56(12):1746-1753. doi: 10.1080/0284186X.2017.1342863. Epub 2017 Jun 29.

PMID:
28661823
18.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.

19.

In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.

Russell J, Pillarsetty N, Kramer RM, Romesser PB, Desai P, Haimovitz-Friedman A, Lowery MA, Humm JL.

Mol Imaging Biol. 2017 Dec;19(6):885-892. doi: 10.1007/s11307-017-1078-6.

20.

Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes.

Creasy JM, Goldman DA, Dudeja V, Lowery MA, Cercek A, Balachandran VP, Allen PJ, DeMatteo RP, Kingham TP, D'Angelica MI, Jarnagin WR.

J Am Coll Surg. 2017 May;224(5):906-916. doi: 10.1016/j.jamcollsurg.2016.12.058. Epub 2017 Feb 13.

21.

Systemic therapy for biliary cancers.

Jordan E, Abou-Alfa GK, Lowery MA.

Chin Clin Oncol. 2016 Oct;5(5):65. doi: 10.21037/cco.2016.10.08.

22.

Current management and future directions in metastatic pancreatic adenocarcinoma.

Varghese AM, Lowery MA, Yu KH, O'Reilly EM.

Cancer. 2016 Dec 15;122(24):3765-3775. doi: 10.1002/cncr.30342. Epub 2016 Sep 20. Review.

23.

The role of novel biologics in biliary cancers.

Jordan E, Braghiroli MF, Lowery MA.

Minerva Gastroenterol Dietol. 2016 Dec;62(4):325-339. Epub 2016 Aug 31. Review.

PMID:
27576672
24.

Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.

Hicks AM, Chou J, Capanu M, Lowery MA, Yu KH, O'Reilly EM.

Clin Colorectal Cancer. 2016 Dec;15(4):360-368. doi: 10.1016/j.clcc.2016.04.014. Epub 2016 May 7.

25.

Young patients with synchronous colorectal liver metastases.

Smith JD, Lowery MA, Fell D, Gallagher DJ, Nash GM, Kemeny NE.

J Surg Oncol. 2016 Apr;113(5):473-6. doi: 10.1002/jso.24181.

26.

Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.

Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM.

Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26. Review.

27.

Identification of germline genetic mutations in patients with pancreatic cancer.

Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK.

Cancer. 2015 Dec 15;121(24):4382-8. doi: 10.1002/cncr.29664. Epub 2015 Oct 6.

28.

Novel Therapeutics for Pancreatic Adenocarcinoma.

Lowery MA, O'Reilly EM.

Hematol Oncol Clin North Am. 2015 Aug;29(4):777-87. doi: 10.1016/j.hoc.2015.04.006. Review.

PMID:
26226910
29.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD.

Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.

30.

Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma.

Li D, Capanu M, Yu KH, Lowery MA, Kelsen DP, O'Reilly EM.

Clin Colorectal Cancer. 2015 Dec;14(4):269-76.e1. doi: 10.1016/j.clcc.2015.05.005. Epub 2015 May 22.

31.

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma.

Sadot E, Doussot A, O'Reilly EM, Lowery MA, Goodman KA, Do RK, Tang LH, Gönen M, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Allen PJ.

Ann Surg Oncol. 2015 Oct;22(11):3512-21. doi: 10.1245/s10434-015-4647-4. Epub 2015 Jun 12.

32.

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.

Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein PJ, Rolfe L, Saif MW, LaValle J, Yu KH, Lowery MA, Allen A, O'Reilly EM.

Pancreatology. 2014 Sep-Oct;14(5):398-402. doi: 10.1016/j.pan.2014.07.003. Epub 2014 Jul 18.

33.

Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer.

Yu KH, Ricigliano M, Hidalgo M, Abou-Alfa GK, Lowery MA, Saltz LB, Crotty JF, Gary K, Cooper B, Lapidus R, Sadowska M, O'Reilly EM.

Clin Cancer Res. 2014 Oct 15;20(20):5281-9. doi: 10.1158/1078-0432.CCR-14-0531. Epub 2014 Aug 8.

34.

DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance.

Liu W, Shia J, Gönen M, Lowery MA, O'Reilly EM, Klimstra DS.

Pancreas. 2014 Nov;43(8):1264-70. doi: 10.1097/MPA.0000000000000190.

PMID:
25058881
35.

A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.

OʼReilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP, DʼAngelica M, Kurtz RC, Abou-Alfa GK, Klimstra DS, Lowery MA, Brennan MF, Coit DG, Reidy DL, Kingham TP, Allen PJ.

Ann Surg. 2014 Jul;260(1):142-8. doi: 10.1097/SLA.0000000000000251.

36.

Treatment of metastatic pancreatic adenocarcinoma: new options and promising strategies.

Lowery MA, O'Reilly EM.

Oncology (Williston Park). 2014 Jan;28(1):76, 78. No abstract available.

37.

Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers.

O'Reilly EM, Lowery MA.

Cancer J. 2012 Nov-Dec;18(6):609-13. doi: 10.1097/PPO.0b013e3182758e27. Review.

PMID:
23187849
38.

Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma.

Epstein AS, Abou-Alfa GK, Shamseddine A, Al-Olayan A, Ang C, Naghy M, Lowery MA, O'Reilly EM.

Gastrointest Cancer Res. 2012 Jul;5(4):130-4. No abstract available.

39.

A 72-year-old man with duodenal adenocarcinoma.

Tamraz S, Shamseddine A, Shah M, El-Oubeidi M, Zaatari G, Geara F, Lowery MA, O'Reilly EM, Al-Kutoubi A, Faraj W, Kelsen DP, Abou-Alfa GK.

Gastrointest Cancer Res. 2012 May;5(3):93-6. No abstract available.

40.

Shallow groundwater mercury supply in a Coastal Plain stream.

Bradley PM, Journey CA, Lowery MA, Brigham ME, Burns DA, Button DT, Chapelle FH, Lutz MA, Marvin-Dipasquale MC, Riva-Murray K.

Environ Sci Technol. 2012 Jul 17;46(14):7503-11. doi: 10.1021/es301540g. Epub 2012 Jul 6.

41.

A case of advanced gastric cancer.

Ang C, Janjigian YY, Shamseddine A, Tawil A, Lowery MA, Intlekofer A, Faraj W, Al-Olayan A, Tang L, O'Reilly EM, Geara F, Al-Kutoubi A, Kelsen DP, Abou-Alfa GK.

Gastrointest Cancer Res. 2012 Mar;5(2):59-63. No abstract available.

42.

Pancreatic cancer: the role of molecular markers in diagnosis and management.

Lowery MA, O'Reilly EM.

Clin Adv Hematol Oncol. 2011 Dec;9(12):900-8. Review.

PMID:
22252658
43.

Genomics and pharmacogenomics of pancreatic adenocarcinoma.

Lowery MA, O'Reilly EM.

Pharmacogenomics J. 2012 Feb;12(1):1-9. doi: 10.1038/tpj.2011.52. Epub 2011 Dec 20. Review.

PMID:
22186617
44.

Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy.

Lowery MA, Klimstra DS, Shia J, Yu KH, Allen PJ, Brennan MF, O'Reilly EM.

Oncologist. 2011;16(12):1714-20. doi: 10.1634/theoncologist.2011-0231. Epub 2011 Oct 31.

45.

An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.

Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O'Reilly EM.

Oncologist. 2011;16(10):1397-402. doi: 10.1634/theoncologist.2011-0185. Epub 2011 Sep 20.

46.

New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.

Lowery MA, O'Reilly EM.

BioDrugs. 2011 Aug 1;25(4):207-16. doi: 10.2165/11592470-000000000-00000.

PMID:
21815696
47.

Spatial and seasonal variability of dissolved methylmercury in two stream basins in the eastern United States.

Bradley PM, Burns DA, Murray KR, Brigham ME, Button DT, Chasar LC, Marvin-Dipasquale M, Lowery MA, Journey CA.

Environ Sci Technol. 2011 Mar 15;45(6):2048-55. doi: 10.1021/es103923j. Epub 2011 Feb 22.

PMID:
21341694
48.

Pancreatic adenocarcinoma: new approaches to a challenging malignancy.

Lowery MA, O'Reilly EM.

Oncology (Williston Park). 2010 Dec;24(14):1339, 1342. No abstract available.

49.

Flood hydrology and methylmercury availability in coastal plain rivers.

Bradley PM, Journey CA, Chapelle FH, Lowery MA, Conrads PA.

Environ Sci Technol. 2010 Dec 15;44(24):9285-90. doi: 10.1021/es102917j. Epub 2010 Nov 16.

PMID:
21080644
50.

How processing digital elevation models can affect simulated water budgets.

Kuniansky EL, Lowery MA, Campbell BG.

Ground Water. 2009 Jan-Feb;47(1):97-107. doi: 10.1111/j.1745-6584.2008.00497.x. Epub 2008 Sep 16.

PMID:
18800972

Supplemental Content

Loading ...
Support Center